Observational study on factors affecting chronic heart failure prognosis
Cohort Study of Chronic Heart Failure
This study looks at how different factors, like genetics and lifestyle, affect the health and future of people with chronic heart failure to help improve their care.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Jiangsu Taizhou People's Hospital Academic / other |
| Locations | 1 site (Taizhou, Jiangsu) |
| Trial ID | NCT05960890 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the factors influencing the prognosis of chronic heart failure in patients. It will collect various omics data, including phenotype, environmental exposure, intestinal microbiome, genome, metabolome, and noninvasive biomarkers, to understand their impact on clinical outcomes. The study focuses on patients with specific types of cardiomyopathy and heart failure symptoms. By analyzing this data, researchers hope to gain insights into improving patient management and outcomes.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with specific types of cardiomyopathy and heart failure symptoms.
Not a fit: Patients with severe renal insufficiency, life expectancy less than 3 months, or cardiac insufficiency from correctable causes may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and management of chronic heart failure, ultimately improving patient outcomes.
How similar studies have performed: Other studies have explored similar factors in heart failure, but this specific approach to integrating multiple omics data is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥18 years; 2. Fulfill at least one of the following criteria：①History of chronic heart failure;②New-onset heart failure with LVEF \<50%；③New-onset heart failure with LVEF≧50%，E/e'≧15 and BNP\>400 pg/mL/NT-proBNP(\<50 years, \>450 pg/mL; 50\~75 years, \>900 pg/mL; \>75 years, \>1800 pg/mL) 3. Etiology: dilated cardiomyopathy, hypertensive heart disease, ischaemic cardiomyopathy, Non-severe valvular heart disease； 4. Primary post-discharge therapy: oral medication; 5. Sign the informed consent form. Exclusion Criteria: 1. Patients with renal failure (Ccr\<30ml/min) or patients on dialysis therapy; 2. Various correctable secondary causes of cardiac insufficiency including hyperthyroid heart disease, anaemic heart disease, uncorrected congenital heart disease; severe valvular heart disease (including severe stenosis or closure of organic aortic and mitral valves); 3. Patients with indications for pacemaker implantation but have not received a pacemaker implant; 4. Patients with chronic obstructive pulmonary disease accompanied by type II respiratory failure. 5. Patients who cannot understand and sign an informed consent form. 6. Patients with mental illness, pregnant women, and other special populations.
Where this trial is running
Taizhou, Jiangsu
- Taizhou People's Hospital affiliated to Nanjing Medical University — Taizhou, Jiangsu, China (Recruiting)
Study contacts
- Principal investigator: Ming Chu, Doctor — Jiangsu Taizhou People's Hospital
- Study coordinator: Yucheng Wu, Doctor
- Email: 2567181759@qq.com
- Phone: +8618360010750
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.